Poly Medicure · risk themes across the available quarters.
Bear-case history
Chinese companies aggressively dumped products in European market due to US-China tariff situation, causing customer inventory reduction from 4-5 months to 2-3 months. While green shoots visible, full recovery uncertain.
50% tariff on India-US trade flagged as unsustainable. While current US revenue <$3.5 million (insulated), uncertainty around US market expansion and CDMO contracts (one US partner) creates execution risk.
Analyst Batra pointedly asked about lessons from being 'caught by surprise' as international growth guidance was revised sharply downward within a year. Management acknowledged signs were visible last quarter but recalibration happened only after Q1 impact.
Government segment declined 10% in Q1 as company exits low-margin business, consistent with strategy but creates near-term revenue headwind until private sector ramp-up compensates.
FDA has stopped accepting Indian lab results for medical device approvals, forcing Poly Medicure to retest all products in US labs. This has reversed prior work and created 6-9 month delays in the approval pipeline.
Chinese competitors increased dumping in Europe due to US tariff diversion; combined with Panama Canal normalization reducing transit times from 2 months to 1 month, customer inventory destocking accelerated unexpectedly.
Full-year renal guidance lowered from ₹220-250 crore to ₹200 crore due to GST-related inventory realignment in Q2. Management expects recovery from Q3 onward but did not quantify impact.
Analyst questioned whether 50% tariff on Indian medical devices is sustainable. Management acknowledged India is 'out of flavor' for US companies who are shifting to Vietnam, Thailand, Malaysia, Indonesia.
Chinese companies using FDA 510(k) route to import products at zero duty into India, severely impacting domestic renal business. Company has raised this concern with government officials. Dialysis machine sales tracking 450 vs. initial 500-600 guidance.
International organic business excluding acquisitions is currently flattish due to European market weakness, MDR transition delays, and NHS contract deferrals. China dumping also affecting export markets globally.
Company strategically reducing government business exposure (from 10-12% to 6-7%) due to lower prices and payment delays, though this impacts overall growth trajectory and market reach.
Newly acquired Pentrocare and CTF Group currently operating at 50-60% capacity utilization with lower EBITDA margins, causing consolidated margins to be lower than standalone. Full impact will be visible in FY27.
Chinese manufacturers circumvent anti-dumping duties by routing through ASEAN (zero import duty). Management is petitioning government for counter duties. Despite 20%+ growth guidance, competition remains fierce with cost inversion against PolyMed's domestic manufacturing.
Red Sea diversions causing shipping bottlenecks and logistics cost inflation. Demand remains intact but supply chain disruptions are delaying execution of pending orders from a region contributing 6-8% of revenue.
CTF and Pendra operating at 12-14% EBITDA margins vs group average, dragging consolidated margins. Q4 subsidiary impact was negative 2.66 crore with calendar Q1 seasonality headwinds. Analyst pressed on receivables normalization (86 days vs 68 days YoY) with management indicating FI27 will see similar DSO levels.
Despite 20% aggregate raw material cost increase and 3-5% price hikes taken, gross margin guidance of 66-68% implies 200-300 bps compression. Management acknowledged current business plan is built on $100-110 crude, leaving limited margin of safety if prices remain elevated.